drugset / Trial / NCT02432053

A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India

NCT02432053 ↗

Phase 4 Completed 92 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

The objective of the study is to demonstrate safety and efficacy of once-daily Advagraf in adult population undergoing kidney or liver transplantation in India.

Timeline

Start
2012-03
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule — —

Indications

No indication recorded.